Osteoarthritis is a leading cause of pain and disability worldwide, an estimated prevalence of 529 million people in 2020 [1]. With aging populations across the globe, this number is expected to rise over the next two decades: cases of knee osteoarthritis (KOA) are projected to increase 74.9% by 2050 [1]. Many different management strategies exist for KOA, such as exercise, physical therapy or pain medication. But, as a progressive disease with no cure, the end result is often patients requiring costly and invasive surgical treatment, such as total joint replacement [2]. This leaves health care systems around the world with an enormous economic burden that is only expected to grow [1]. Understandably, there is considerable interest in nonoperative treatment, especially those with the potential to slow or reverse the progression of the disease [2]. Enter, intraarticular injections like platelet-rich plasma (PRP). Late 20th century pre-clinical research on PRP was encouraging [3]. Its mechanisms for promoting tissue regeneration made it a promising treatment for a variety of conditions, including KOA, where the high concentration of growth factors and cytokines could potentially counteract important aspects of KOA pathophysiology...